Follow Xeris Biopharma Holdings, Inc.. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.
6 Stories in coverage 33 approved Programs 0 Registered trials 10-Q Nov 5 Latest SEC filing Nov 3 Latest story
Timeline 6 Pipeline 3 Trials 0
Pipeline by stage
Approved 3
Details
Headquarters Chicago, IL Industry Pharmaceutical Preparations Also known as XERS How the company describes itself Xeris Biopharma commercializes Recorlev for Cushing's syndrome, Gvoke (liquid glucagon) for severe hypoglycemia, and Keveyis for primary periodic paralysis. The company develops XP-8121, a Phase 3-ready subcutaneous injection for hypothyroidism, and has early-stage programs using XeriSol and XeriJect platforms. Based in Chicago. source